Terms: = Head and neck cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Staging
27 results:
1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
2. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian T; Liu D; Cao G; Chen Z; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
[TBL] [Abstract] [Full Text] [Related]
3. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract] [Full Text] [Related]
4. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract] [Full Text] [Related]
5. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract] [Full Text] [Related]
6. Perioperative Durvalumab for Resectable Non-Small-Cell Lung cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract] [Full Text] [Related]
7. Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNIcancer, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).
Veziant J; Bouché O; Aparicio T; Barret M; El Hajbi F; Lepilliez V; Lesueur P; Maingon P; Pannier D; Quero L; Raoul JL; Renaud F; Seitz JF; Serre AA; Vaillant E; Vermersch M; Voron T; Tougeron D; Piessen G; ; ; ; ; ; ; ; ; ;
Dig Liver Dis; 2023 Dec; 55(12):1583-1601. PubMed ID: 37635055
[TBL] [Abstract] [Full Text] [Related]
8. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic stratification of oropharyngeal cancer patients in a betel nut chewing and low HPV area.
Lee HP; Lee CC
J Otolaryngol Head Neck Surg; 2023 Apr; 52(1):27. PubMed ID: 37081578
[TBL] [Abstract] [Full Text] [Related]
10. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract] [Full Text] [Related]
11. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/pd-l1 Inhibitors Combined with Chemotherapy.
Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
[TBL] [Abstract] [Full Text] [Related]
12. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor pd-l1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.
Zhang S; Cai H; Huang J; Wang G
Thorac Cancer; 2022 Dec; 13(23):3284-3294. PubMed ID: 36288460
[TBL] [Abstract] [Full Text] [Related]
13. Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.
Pharaon RR; Gernon T; Chang S; Vora N; Villaflor VM; Bell D; Afkhami M; Amini A; Sampath S; Kang R; Maghami EG; Massarelli E
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483880
[TBL] [Abstract] [Full Text] [Related]
14. Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in head and neck Lymphoepithelioma-Like Carcinoma.
Zou WQ; Luo WJ; Feng YF; Liu F; Liang SB; Fang XL; Liang YL; Liu N; Wang YQ; Mao YP
Front Immunol; 2022; 13():818411. PubMed ID: 35140722
[TBL] [Abstract] [Full Text] [Related]
15. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced head and neck Squamous Cell Carcinoma: A Phase IB Study.
Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
[TBL] [Abstract] [Full Text] [Related]
16. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
Wang YQ; Zhang Y; Jiang W; Chen YP; Xu SY; Liu N; Zhao Y; Li L; Lei Y; Hong XH; Liang YL; Li JY; Zhang LL; Yun JP; Sun Y; Li YQ; Ma J
J Immunother Cancer; 2019 Nov; 7(1):298. PubMed ID: 31722750
[TBL] [Abstract] [Full Text] [Related]
17. Expression and clinical value of pd-l1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract] [Full Text] [Related]
18. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
19. Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma.
Heiden BT; Patel N; Nancarrow DJ; Hermann M; Brown RKJ; Orringer MB; Lin J; Chang AC; Carrott PW; Lynch WR; Zhao L; Beer DG; Reddy RM
J Surg Res; 2018 Dec; 232():621-628. PubMed ID: 30463782
[TBL] [Abstract] [Full Text] [Related]
20. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.
Duan J; Xie Y; Qu L; Wang L; Zhou S; Wang Y; Fan Z; Yang S; Jiao S
J Immunother Cancer; 2018 Oct; 6(1):100. PubMed ID: 30285868
[TBL] [Abstract] [Full Text] [Related]
[Next]
